"Item Id","Item URI","Dublin Core:Title","Dublin Core:Subject","Dublin Core:Description","Dublin Core:Creator","Dublin Core:Source","Dublin Core:Publisher","Dublin Core:Date","Dublin Core:Contributor","Dublin Core:Rights","Dublin Core:Relation","Dublin Core:Format","Dublin Core:Language","Dublin Core:Type","Dublin Core:Identifier","Dublin Core:Coverage","Item Type Metadata:Bibliography","Item Type Metadata:Biographical Text","Item Type Metadata:Occupation","Item Type Metadata:Death Date","Item Type Metadata:Birthplace","Item Type Metadata:Text","Item Type Metadata:Player","Item Type Metadata:Access","Item Type Metadata:Alternate URL","Item Type Metadata:Citation","Item Type Metadata:Accessibility","Item Type Metadata:Abstract","Item Type Metadata:Read Online","Item Type Metadata:Additional Exercise","Item Type Metadata:Email Body","Item Type Metadata:Interviewer","Item Type Metadata:Interviewee","Item Type Metadata:Location","Item Type Metadata:Transcription","Item Type Metadata:Local URL","Item Type Metadata:Original Format","Item Type Metadata:Physical Dimensions","Item Type Metadata:Duration","Item Type Metadata:Compression","Item Type Metadata:Producer","Item Type Metadata:Director","Item Type Metadata:Bit Rate/Frequency","Item Type Metadata:Time Summary","Item Type Metadata:Birth Date","Item Type Metadata:Subject Line","Item Type Metadata:From","Item Type Metadata:To","Item Type Metadata:CC","Item Type Metadata:BCC","Item Type Metadata:Number of Attachments","Item Type Metadata:Standards","Item Type Metadata:Objectives","Item Type Metadata:Materials","Item Type Metadata:Lesson Plan Text","Item Type Metadata:URL","Item Type Metadata:Event Type","Item Type Metadata:Participants","PDF Text:Text",tags,file,itemType,collection,public,featured
424,https://repository.netecweb.org/items/show/424,"A Novel Approach to Infectious Disease Preparedness: Incorporating Investigational Therapeutics and Research Objectives into Full-Scale Exercises",Research,"The use of investigational therapeutics in the care of patients with Ebola virus disease was documented in the literature following the 2013-2016 outbreak. In order to access these types of therapeutics, facilities must have processes in place to quickly and efficiently activate study protocols, obtain the medications, and administer them in a timely manner.","Angela Vasa, Syra Madad, LuAnn Larson, Colleen S. Kraft, Sharon Vanairsdale, Jonathan D. Grein, Jennifer Garland, Virginia “Madison” Butterworth, and Christopher J. Kratochvil.",,,2019-02-19,,,"Y - D0.1Res/D0.2Res Qualtrics # 1306, original # 4",,,Publication,,,,,,,,,,,,"Vasa, Angela, Syra Madad, LuAnn Larson, Colleen S. Kraft, Sharon Vanairsdale, Jonathan D. Grein, Jennifer Garland, Virginia “Madison” Butterworth, and Christopher J. Kratochvil. 2019. ""A Novel Approach to Infectious Disease Preparedness: Incorporating Investigational Therapeutics and Research Objectives into Full-Scale Exercises."" Health security 17 (1):54-61.","Free online","
Abstract
The use of investigational therapeutics in the care of patients with Ebola virus disease was documented in the literature following the 2013-2016 outbreak. In order to access these types of therapeutics, facilities must have processes in place to quickly and efficiently activate study protocols, obtain the medications, and administer them in a timely manner. Testing these procedures in advance of a real-world event is crucial to ensuring successful implementation and execution. Drills and exercises are routinely used as part of the emergency preparedness planning process, as they provide a low-risk environment in which to test plans and procedures. Including research activities in full-scale emergency preparedness exercises is a novel approach that should be considered when creating a comprehensive special pathogen program. One important aspect of creating an agile response program is developing and sustaining strong relationships with key collaborators. Including departments not previously engaged in infectious disease preparedness exercises provides a forum to strengthen these relationships, clarify roles, and identify gaps. This article describes the process used to incorporate research-centric objectives focused on the use of investigational therapeutics for Ebola virus disease into a full-scale exercise, the evaluation process used to measure the identified objectives, and the results of the exercise.
This article describes the process used to incorporate research-centric objectives focused on the use of investigational therapeutics for Ebola virus disease into a full-scale exercise, the evaluation process used to measure the identified objectives, and the results of the exercise.
",,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.liebertpub.com/doi/10.1089/hs.2018.0100?utm_source=sfmc&utm_medium=email&utm_campaign=HS%20FP%20Feb%2028%202019&d=2/28/2019&mcid=439528526,,,,"Exercises and Drills,Experimental Drugs,R-Res&Pub,Research,Therapeutics",,Publication,Discover,1,0
316,https://repository.netecweb.org/items/show/316,"Are We Ready for the Next Outbreak?",General,"A three part pod-cast series discusses the need for new and improved tools to fight infectious disease, as demonstrated by the recent outbreaks of Ebola and Zika.","U.S. Agency for International Development",,,2018-04-01,,,,,,,,,,,,,,,"",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://soundcloud.com/user-972010434-53971567/sets/are-we-ready-for-the-next-outbreak,,,,"Ebola,Epidemic,Epidemiology,Experimental Drugs,Federal,International Response,Medical Surveillance,Outbreaks,Pandemic,Prophylaxis,Public Health,R-Gen",,Webinar,Discover,1,0
312,https://repository.netecweb.org/items/show/312,"Prioritizing diseases for research and development in emergency contexts",General,"Worldwide, the number of potential pathogens is very large, while the resources for disease research and development (R&D) is limited. To ensure efforts under WHO’s R&D Blueprint are focused and productive, a list of diseases and pathogens are prioritized for R&D in public health emergency contexts.","World Health Organization",,,2022,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.who.int/activities/prioritizing-diseases-for-research-and-development-in-emergency-contexts,,,,"Coronavirus,Crimean Congo Haemorrhagic Fever (CCHF),Ebola,Epidemic,Experimental Drugs,Lassa,Marburg,Medical Surveillance,MERS-CoV,Mpox,Orthopox Virus,Outbreaks,Pandemic,Plague,Prophylaxis,Public Health,R-Gen,Respiratory Pathogen,SARS,Special Pathogens,Therapeutics,Vaccine Study,Variola,Viral Hemorrhagic Fever",https://repository.netecweb.org/files/original/8df853d7cbf6e38897cc9822e2f157b2.png,Guide,Discover,1,0
310,https://repository.netecweb.org/items/show/310,"Products Approved for Other Bioterrorism Emergencies","Treatment & Care","This site lists products for Botulism due to Clostridium botulinum toxin; Ebola Virus Disease (EVD); Glanders and Melioidosis due to Burkholderia mallei and B. pseudomallei, respectively; Plague due to Yersinia pestis; Smallpox due to Variola major and Variola minor; Tularemia due to Francisella tularensis; and Zika Virus Disease.","U.S. Food and Drug Administration",,,2017-09-08,"2022-09-27 - general asset review - Treatment & Care group",,,,,,,2025-09-27,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm063804.htm,,,,"Coronavirus,Ebola,Experimental Drugs,MERS-CoV,Orthopox Virus,Plague,Prophylaxis,R-T&C,Respiratory Pathogen,Smallpox,Special Pathogens,Therapeutics,Viral Hemorrhagic Fever",,Guide,Develop,1,0
131,https://repository.netecweb.org/items/show/131,"After the Ebola Outbreak: Lessons Learned",General,"In the wake of caring for four patients with active Ebola virus in 2014, Emory clinicians have taken stock of lessons learned in infectious disease prevention, therapeutic care, and health aftereffects and are sharing that information broadly with other health care professionals and first responders.","Loftus, Mary (editor), Emory Medicine",,,2018-02-20,"2022-01-10 by PPE group Shawn Gibbs",,,,,,,2025-01-10,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,http://emorymedicinemagazine.emory.edu/issues/2018/winter/briefs/after_ebola_outbreak_ppe/index.html,,,,"Critical Care,Ebola,Experimental Drugs,Follow up,Infection Prevention and Control,Nursing,Patient Care,Personal Protective Equipment (PPE),Prophylaxis,R-PPE,Survivors,Therapeutics,Training,Translational Research",https://repository.netecweb.org/files/original/19abe3d83dc05c0ccdd1270c93f43e4a.png,Hyperlink,Discover,1,0
108,https://repository.netecweb.org/items/show/108,"The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States",Research,"The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management.","Kraft, C. S., A. L. Hewlett, S. Koepsell, A. M. Winkler, C. J. Kratochvil, L. Larson, J. B. Varkey, A. K. Mehta, G. M. Lyon, 3rd, R. J. Friedman-Moraco, V. C. Marconi, C. E. Hill, J. N. Sullivan, D. W. Johnson, S. J. Lisco, M. J. Mulligan, T. M. Uyeki, A. K. McElroy, T. Sealy, S. Campbell, C. Spiropoulou, U. Stroher, I. Crozier, R. Sacra, M. J. Connor, Jr., V. Sueblinvong, H. A. Franch, P. W. Smith, B. S. Ribner, U. Nebraska Biocontainment and U. the Emory Serious Communicable Diseases",,,2015-08-15,,,,,,Publication,,,,,,,,,,,,"Kraft, C. S., A. L. Hewlett, S. Koepsell, A. M. Winkler, C. J. Kratochvil, L. Larson, J. B. Varkey, A. K. Mehta, G. M. Lyon, 3rd, R. J. Friedman-Moraco, V. C. Marconi, C. E. Hill, J. N. Sullivan, D. W. Johnson, S. J. Lisco, M. J. Mulligan, T. M. Uyeki, A. K. McElroy, T. Sealy, S. Campbell, C. Spiropoulou, U. Stroher, I. Crozier, R. Sacra, M. J. Connor, Jr., V. Sueblinvong, H. A. Franch, P. W. Smith, B. S. Ribner, U. Nebraska Biocontainment and U. the Emory Serious Communicable Diseases (2015). ""The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States."" Clin Infect Dis 61(4): 496-502.","free online - Pubmed Central","BACKGROUND: The current West Africa Ebola virus disease (EVD) outbreak has resulted in multiple individuals being medically evacuated to other countries for clinical management. METHODS: We report two patients who were transported from West Africa to the United States for treatment of EVD. Both patients received aggressive supportive care measures, as well as an investigational therapeutic (TKM-100802) and convalescent plasma. RESULTS: While one patient experienced critical illness with multi-organ failure requiring mechanical ventilation and renal replacement therapy, both patients recovered without serious long-term sequelae to date. CONCLUSIONS: It is unclear what role the experimental drug and convalescent plasma had in the recovery of these patients. Prospective clinical trials are needed to delineate the role of investigational therapies in the care of patients with EVD.",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542597/,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25904375,,,,"Critical Care,Ebola,Experimental Drugs,Patient Care,R-Res&Pub,Therapeutics",https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4542597/pdf/civ334.pdf,Publication,Develop,1,0
107,https://repository.netecweb.org/items/show/107,"Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease",Research,"Since the discovery of Ebola virus in the Democratic Republic of Congo in 1976, outbreaks of EVD had been mainly confined to rural areas (http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html)...","Kraft, C. S.",,,2016-11-15,,,,,,Publication,,,,,,,,,,,,"Kraft, C. S. (2016). ""Editorial Commentary: Considerations of Favipiravir as a Medical Countermeasure in Future Randomized Controlled Trials Against Ebola Virus Disease."" Clin Infect Dis 63(10): 1295-1296.","free online - Oxford Academic",,https://academic.oup.com/cid/article/63/10/1295/2450073,,,,,,,,,,,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27553374,,,,"Clinical Trial,Ebola,Experimental Drugs,Patient Care,R-Res&Pub,Therapeutics",http://repository.netecweb.org/pdfs/ciw575.pdf,Publication,Develop,1,0